S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
BOSTON - Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a micro-cap biotech company currently valued at $8.77 million and trading at $6.96, will present clinical data from its Phase 1/2 trial of solnerstotug, alone and in combination with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab), at the upcoming European Society for Medical Oncology Congress in Berlin. According to InvestingPro analysis, the company appears undervalued despite its stock declining over 30% year-to-date.
The presentation, scheduled for October 17, 2025, will feature results from the dose expansion cohort studying patients with advanced solid tumors that have shown resistance to prior PD-(L)1 therapy. While maintaining a strong liquidity position with more cash than debt and a current ratio of 6.82, InvestingPro data reveals the company is rapidly burning through its cash reserves. Get access to 6 more exclusive InvestingPro Tips and comprehensive financial analysis to make informed investment decisions.
Dr. Kyriakos Papadopoulos, Co-Director of Clinical Research at START in San Antonio, will deliver the presentation titled "Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD-(L)1 therapy."
Solnerstotug is Sensei’s lead product candidate, designed as a conditionally active antibody that blocks the VISTA checkpoint selectively within the low pH tumor microenvironment. According to the company, VISTA acts as a suppressor of T cells by binding the receptor PSGL-1.
The clinical-stage biotechnology company focuses on developing what it calls Tumor Microenvironment Activated biologics (TMAb), which are conditionally active therapeutics designed to function specifically within the tumor microenvironment.
The information in this article is based on a press release statement from Sensei Biotherapeutics.
In other recent news, Sensei Biotherapeutics, Inc. announced a one-for-twenty reverse stock split of its common stock, which will take effect on June 16, 2025. This strategic decision was approved by stockholders at the annual meeting on May 21, 2025, and aims to comply with Nasdaq Capital Market’s minimum bid price requirement for continued listing. Additionally, the board has decided to reduce the total number of authorized shares from 250 million to 12.5 million. In another development, H.C. Wainwright analysts assumed coverage of Sensei Biotherapeutics with a Buy rating, setting a price target of $5.00. The analysts cited the company’s innovative approach to developing immune checkpoint inhibitors as a key factor for their positive outlook. At the recent stockholders’ meeting, two board directors, William Ringo and John Celebi, were elected to serve until the 2028 annual meeting. The meeting had a significant turnout, with 65.92% of the outstanding shares represented. These developments highlight the company’s ongoing strategic initiatives and investor interest.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.